UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis

Viruses, 2022-10, Vol.14 (10), p.2281

2022

Volltextzugriff (PDF)

Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid

European journal of medicinal chemistry, 2018-04, Vol.150, p.930-945

2018

Volltextzugriff (PDF)

Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study

Molecules (Basel, Switzerland), 2022-06, Vol.27 (12), p.3660

2022

Volltextzugriff (PDF)

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia

Cancers, 2021-02, Vol.13 (5), p.1003

2021

Volltextzugriff (PDF)

Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3

ACS medicinal chemistry letters, 2019-04, Vol.10 (4), p.437-443

2019

Volltextzugriff (PDF)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia

Cell death & disease, 2022-06, Vol.13 (6), p.576-13, Article 576

2022

Volltextzugriff (PDF)

The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses

Microorganisms (Basel), 2021-08, Vol.9 (8), p.1731

2021

Volltextzugriff (PDF)

N -Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK

MedChemComm, 2018, Vol.9 (6), p.963-968

2018

Volltextzugriff (PDF)

A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats

Brain sciences, 2021-12, Vol.12 (1), p.35

2021

Volltextzugriff (PDF)

Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis

Biomolecules (Basel, Switzerland), 2023-09, Vol.13 (9), p.1349

2023

Volltextzugriff (PDF)

AKR1C3 is a biomarker and druggable target for oropharyngeal tumors

Cellular oncology (Dordrecht), 2021-04, Vol.44 (2), p.357-372

2021

Volltextzugriff (PDF)

Dihydroorotate dehydrogenase inhibitors in anti-infective drug research

European journal of medicinal chemistry, 2019-12, Vol.183, p.111681-111681, Article 111681

2019

Volltextzugriff (PDF)

Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

Journal of cancer metastasis and treatment, 2017-12, Vol.3 (12), p.328

2017

Volltextzugriff (PDF)

Phenothiazines as anti-cancer agents: SAR overview and synthetic strategies

European journal of medicinal chemistry, 2023-06, Vol.254, p.115337-115337, Article 115337

2023

Volltextzugriff (PDF)

Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication

Antiviral research, 2021-05, Vol.189, p.105057-105057, Article 105057

2021

Volltextzugriff (PDF)

Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor

FEBS letters, 2023-08, Vol.597 (16), p.2119-2132

2023

Volltextzugriff (PDF)

Tandem mass spectrometry of homologous 3‐hydroxyfurazan and nitrile amino acids: Analysis of cooperative interactions and fragmentation processes

Journal of mass spectrometry., 2024-06, Vol.59 (6), p.e5043-n/a

2024

Volltextzugriff (PDF)

Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication

Antiviral research, 2023-11, Vol.219, p.105734-105734, Article 105734

2023

Volltextzugriff (PDF)

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

Recent patents on anti-cancer drug discovery, 2018-01, Vol.13 (1), p.86

2018

Volltextzugriff (PDF)

Use of the furoxan (1,2,5-oxadiazole 2-oxide) system in the design of new NO-donor antioxidant hybrids

ARKIVOC, 2006-01, Vol.2006 (7), p.301-309

2006

Volltextzugriff (PDF)

Targeting Myeloid Differentiation Using Potent 2‑Hydroxypyrazolo[1,5‑a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors

Journal of medicinal chemistry, 2018-07, Vol.61 (14), p.6034-6055

2018

Volltextzugriff (PDF)

The Novel Ih/IDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis

Viruses, 2022-10, Vol.14 (10)

2022

Volltextzugriff (PDF)

An alternative conformation of the N‐terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent

Acta crystallographica. Section D, Biological crystallography., 2024-06, Vol.80 (6), p.386-396

2024

Volltextzugriff (PDF)

New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold

European journal of medicinal chemistry, 2022-07, Vol.237, p.114366-114366, Article 114366

2022

Volltextzugriff (PDF)

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2‑Hydroxypyrazolo[1,5‑a]pyridine Scaffold: SAR of the Biphenyl Moiety

Journal of medicinal chemistry, 2021-05, Vol.64 (9), p.5404-5428

2021

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(101)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis

Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid

Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study

The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia

Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia

The New Generation hDHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses

N -Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK

A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats

Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis

AKR1C3 is a biomarker and druggable target for oropharyngeal tumors

Dihydroorotate dehydrogenase inhibitors in anti-infective drug research

Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention

Phenothiazines as anti-cancer agents: SAR overview and synthetic strategies

Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication

Biochemical characterization of Mycobacterium tuberculosis dihydroorotate dehydrogenase and identification of a selective inhibitor

Tandem mass spectrometry of homologous 3‐hydroxyfurazan and nitrile amino acids: Analysis of cooperative interactions and fragmentation processes

Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication

Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy

Use of the furoxan (1,2,5-oxadiazole 2-oxide) system in the design of new NO-donor antioxidant hybrids

Targeting Myeloid Differentiation Using Potent 2‑Hydroxypyrazolo[1,5‑a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors

The Novel Ih/IDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis

An alternative conformation of the N‐terminal loop of human dihydroorotate dehydrogenase drives binding to a potent antiproliferative agent

New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold

Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2‑Hydroxypyrazolo[1,5‑a]pyridine Scaffold: SAR of the Biphenyl Moiety

Suchergebnisse filtern